

Andrew S Herbert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9430264/publications.pdf>

Version: 2024-02-01

47
papers

4,477
citations

172386

29
h-index

243529

44
g-index

55
all docs

55
docs citations

55
times ranked

7987
citing authors

#	ARTICLE	IF	CITATIONS
1	Broad neutralization of SARS-related viruses by human monoclonal antibodies. <i>Science</i> , 2020, 369, 731-736.	6.0	534
2	Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. <i>Science</i> , 2020, 369, 1261-1265.	6.0	520
3	Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. <i>Science</i> , 2021, 371, 823-829.	6.0	285
4	Lassa virus entry requires a trigger-induced receptor switch. <i>Science</i> , 2014, 344, 1506-1510.	6.0	251
5	Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 5034-5039.	3.3	246
6	Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes. <i>Science</i> , 2021, 372, 1108-1112.	6.0	210
7	A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. <i>Cell Host and Microbe</i> , 2018, 24, 221-233.e5.	5.1	182
8	A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition. <i>Cell Host and Microbe</i> , 2020, 28, 486-496.e6.	5.1	178
9	Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization. <i>Journal of Clinical Investigation</i> , 2020, 130, 6728-6738.	3.9	172
10	Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses. <i>Cell</i> , 2017, 169, 878-890.e15.	13.5	145
11	Filovirus receptor NPC1 contributes to species-specific patterns of ebolavirus susceptibility in bats. <i>ELife</i> , 2015, 4, .	2.8	110
12	NRP2 and CD63 Are Host Factors for Lujo Virus Cell Entry. <i>Cell Host and Microbe</i> , 2017, 22, 688-696.e5.	5.1	108
13	A "Trojan horse" bispecific-antibody strategy for broad protection against ebolaviruses. <i>Science</i> , 2016, 354, 350-354.	6.0	101
14	Haploid Genetic Screen Reveals a Profound and Direct Dependence on Cholesterol for Hantavirus Membrane Fusion. <i>MBio</i> , 2015, 6, e00801.	1.8	100
15	Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses. <i>Journal of Virology</i> , 2016, 90, 266-278.	1.5	92
16	Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Protects Nonhuman Primates from Intramuscular and Aerosol Challenge with Ebolavirus. <i>Journal of Virology</i> , 2013, 87, 4952-4964.	1.5	87
17	Protocadherin-1 is essential for cell entry by New World hantaviruses. <i>Nature</i> , 2018, 563, 559-563.	13.7	84
18	Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection. <i>Cell Host and Microbe</i> , 2019, 25, 39-48.e5.	5.1	83

#	ARTICLE	IF	CITATIONS
19	A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates. <i>Cell Host and Microbe</i> , 2019, 25, 49-58.e5.	5.1	82
20	Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site. <i>Cell Reports</i> , 2016, 15, 1514-1526.	2.9	80
21	Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein. <i>Journal of Virology</i> , 2016, 90, 279-291.	1.5	72
22	Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus. <i>Cell Reports</i> , 2017, 19, 413-424.	2.9	66
23	Niemann-Pick C1 Is Essential for Ebolavirus Replication and Pathogenesis <i>In Vivo</i> . <i>MBio</i> , 2015, 6, e00565-15.	1.8	65
24	Filovirus RefSeq Entries: Evaluation and Selection of Filovirus Type Variants, Type Sequences, and Names. <i>Viruses</i> , 2014, 6, 3663-3682.	1.5	49
25	Novel Small Molecule Entry Inhibitors of Ebola Virus. <i>Journal of Infectious Diseases</i> , 2015, 212, S425-S434.	1.9	49
26	Calcium Regulation of Hemorrhagic Fever Virus Budding: Mechanistic Implications for Host-Oriented Therapeutic Intervention. <i>PLoS Pathogens</i> , 2015, 11, e1005220.	2.1	42
27	Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever. <i>Cell</i> , 2021, 184, 3486-3501.e21.	13.5	39
28	Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle. <i>Scientific Reports</i> , 2016, 6, 24897.	1.6	35
29	A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants. <i>MBio</i> , 2021, 12, e0247321.	1.8	35
30	Cysteine Cathepsin Inhibitors as Anti-Ebola Agents. <i>ACS Infectious Diseases</i> , 2016, 2, 173-179.	1.8	33
31	Structural basis of broad ebolavirus neutralization by a human survivor antibody. <i>Nature Structural and Molecular Biology</i> , 2019, 26, 204-212.	3.6	30
32	Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy. <i>International Journal of Biological Macromolecules</i> , 2021, 183, 203-212.	3.6	28
33	A Single Residue in Ebola Virus Receptor NPC1 Influences Cellular Host Range in Reptiles. <i>MSphere</i> , 2016, 1, .	1.3	25
34	Longitudinal peripheral blood transcriptional analysis of a patient with severe Ebola virus disease. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	23
35	Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice. <i>Journal of Virology</i> , 2017, 91, .	1.5	23
36	Development of an antibody cocktail for treatment of Sudan virus infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 3768-3778.	3.3	23

#	ARTICLE	IF	CITATIONS
37	Post-Exposure Protection in Mice against Sudan Virus by a Two Antibody Cocktail. <i>Viruses</i> , 2018, 10, 286.	1.5	16
38	Human antibody recognizing a quaternary epitope in the Puumala virus glycoprotein provides broad protection against orthohantaviruses. <i>Science Translational Medicine</i> , 2022, 14, eabl5399.	5.8	16
39	Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses. <i>Journal of Experimental Medicine</i> , 2017, 214, 2563-2572.	4.2	15
40	Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 47, 116393.	1.4	15
41	Correspondence of Neutralizing Humoral Immunity and CD4 T Cell Responses in Long Recovered Sudan Virus Survivors. <i>Viruses</i> , 2016, 8, 133.	1.5	8
42	Two Distinct Lysosomal Targeting Strategies Afford Trojan Horse Antibodies With Pan-Filovirus Activity. <i>Frontiers in Immunology</i> , 2021, 12, 729851.	2.2	5
43	Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naïve and Experienced Individuals. <i>Viruses</i> , 2022, 14, 370.	1.5	5
44	Characterization of an Anti-Ebola virus Hyperimmune Globulin Derived from Convalescent Plasma. <i>Journal of Infectious Diseases</i> , 2021, , .	1.9	3
45	Multiple viral proteins and immune response pathways act to generate robust long-term immunity in Sudan virus survivors. <i>EBioMedicine</i> , 2019, 46, 215-226.	2.7	2
46	Neutralizing Antibodies against Crimeanâ€“Congo Hemorrhagic Fever Virus Derived from a Human Survivor. <i>Proceedings (mdpi)</i> , 2020, 50, .	0.2	0
47	Mapping the Interface between New World Hantaviruses and Their Receptor, PCDH1. <i>Proceedings (mdpi)</i> , 2020, 50, .	0.2	0